La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Beam Therapeutics Croissance future
Future contrôle des critères 0/6
Beam Therapeutics's revenue and earnings are forecast to decline at 30.9% and 14.4% per annum respectively. EPS is expected to decline by 12.5% per annum. Return on equity is forecast to be -105.5% in 3 years.
Informations clés
-14.4%
Taux de croissance des bénéfices
-12.5%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 0% |
| Taux de croissance des recettes | -30.9% |
| Rendement futur des capitaux propres | -105.5% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 23 Apr 2024 |
Mises à jour récentes de la croissance future
Pas de mise à jour
Recent updates
Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 57 | -492 | -333 | -314 | 5 |
| 12/31/2025 | 64 | -447 | -373 | -366 | 12 |
| 12/31/2024 | 63 | -452 | -366 | -356 | 14 |
| 12/31/2023 | 378 | -133 | -183 | -149 | N/A |
| 9/30/2023 | 82 | -285 | -392 | -353 | N/A |
| 6/30/2023 | 80 | -298 | -380 | -338 | N/A |
| 3/31/2023 | 77 | -287 | -353 | -306 | N/A |
| 12/31/2022 | 61 | -289 | -26 | 23 | N/A |
| 9/30/2022 | 92 | -315 | 39 | 94 | N/A |
| 6/30/2022 | 77 | -234 | 123 | 171 | N/A |
| 3/31/2022 | 60 | -238 | 148 | 191 | N/A |
| 12/31/2021 | 52 | -371 | -113 | -66 | N/A |
| 9/30/2021 | 1 | -401 | -134 | -92 | N/A |
| 6/30/2021 | 0 | -408 | -155 | -117 | N/A |
| 3/31/2021 | 0 | -366 | -132 | -107 | N/A |
| 12/31/2020 | 0 | -196 | -112 | -96 | N/A |
| 9/30/2020 | 0 | -132 | -100 | -89 | N/A |
| 6/30/2020 | 0 | -119 | -94 | -85 | N/A |
| 3/31/2020 | 0 | -106 | -87 | -74 | N/A |
| 12/31/2019 | 0 | -91 | -85 | -72 | N/A |
| 9/30/2019 | 0 | -86 | -79 | -57 | N/A |
| 6/30/2019 | 0 | -134 | -70 | -50 | N/A |
| 3/31/2019 | N/A | -124 | -57 | -42 | N/A |
| 12/31/2018 | N/A | -117 | -33 | -20 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: BEAM * is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: BEAM * is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: BEAM * is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: BEAM *'s revenue is expected to decline over the next 3 years (-30.9% per year).
Croissance élevée des revenus: BEAM *'s revenue is forecast to decline over the next 3 years (-30.9% per year).
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: BEAM * is forecast to be unprofitable in 3 years.